Cybin (CYBN) announced that the United States Patent and Trademark Office has granted U.S. patent 12,291,499 in support of its CYB003 program in MDD. The patent, which is expected to provide exclusivity until 2041, includes claims to pharmaceutical compositions and oral dosage forms within the Company’s proprietary deuterated psilocin analog program, CYB003.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin Secures New U.S. Patent for CYB003 Program in Major Depressive Disorder
- Cybin CEO to Speak at Milken Institute Global Conference on Medical Breakthroughs
- Psychedelic: Clearmind completes clinical site initiations for AUD trial
- Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials
- Cybin announces additional CYB003 strategic partnership agreements